Announced Mon, 3 Aug · 17:24 IST
Strides Pharma Q1 FY27: 13% revenue growth, EBITDA margin steady at 18.2%
Mgmt Guided Margin ImprovementMgmt Guided Margin PressurePromoter Disclosed Acquisition PlansOrder Pipeline DisclosedAnalyst Day Multiyear TargetsCfo Debt Reduction RoadmapInvestor Communications View source PDFExplain this filing
STAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-5.5%1-day move
₹1024.50
prior close
₹1029.10
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.2+0.1-0.1-0.2-5.5-2.5-2.2-2.7-1.9-3.9————
Up moveDown movePending
AI summary
Q1 FY27: Revenue up 13% YoY. US at $68M, Ex-US up 17% at $63M. Gross margin expanded to 60.9%. EBITDA margin steady at 18.2% despite extra Rs131M in freight and geopolitical costs. Operational PAT up 8% to Rs123.1 crore. Reported PAT up 57% to Rs165.5 crore, boosted by Pivot Path divestment gain. CARE rating upgraded to A+. Targets $375M North America business by FY28.
Likely market impact
Steady quarter with margin resilience despite cost pressures. US business H2-weighted with 10 launches planned. Debt reduction on track.